Updates on Chemotherapy-Induced Nausea and Vomiting Management

Slideshow

This slideshow reviews the latest clinical updates surrounding the management of treatment-associated nausea and vomiting, including recommendations, newly approved agents, and more.

Nausea and vomiting are known unwanted side effects associated with cancer treatment, including chemotherapy. In some cases, chemotherapy-induced nausea and vomiting (CINV) can be debilitating for patients, and prevention is key. These slides provide insight into CINV management, recent drug approvals in this area, and current treatment recommendations.

Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
3 experts are featured in this series.
3 experts are featured in this series.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Genomic Features May Define Patient Selection in KRAS-mutated NSCLC

Roman Fabbricatore
February 4th 2025
Article

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer

Russ Conroy
February 4th 2025
Article

Data from analytical similarity studies and comparative clinical trials support the application of HLX11 in HER2-positive breast cancer.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Tim Cortese
February 3rd 2025
Article

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

Best Practices for Boosting the Enrollment of Underserved Populations in Cancer Clinical Trials

Best Practices for Boosting the Enrollment of Underserved Populations in Cancer Clinical Trials

Coral Omene, MD, PhD;Mariam Eskander, MD, MPH
February 3rd 2025
Article

Coral Omene, MD, PhD, and Mariam Eskander, MD, MPH, discuss how to continue engagement in clinical trial enrollment for underserved populations.